North America remains the largest market, accounting for roughly 38% of the High‑Throughput Mass Spectrometer market growth. Key drivers include robust pharmaceutical R&D budgets, sustained federal research grants, and a mature service ecosystem that accelerates instrument adoption. Europe follows with about 30% share, propelled by EU Horizon Europe funding, a dense network of biotech clusters, and harmonized regulatory pathways that streamline deployments. Asia Pacific, the fastest‑growing region, captures an estimated 22% and is expected to outpace peers in the regional forecast; growth is fueled by massive government investments in China and India, rapid expansion of clinical‑trial laboratories, and a surge in private‑equity‑backed biotech ventures. Latin America contributes around 6%, driven by increasing public‑health initiatives, rising demand for personalized medicine, and improving laboratory infrastructure in Brazil and Mexico. The Middle East & Africa hold roughly 4% of the market, with growth underpinned by sovereign‑wealth‑fund allocations to healthcare modernization, strategic partnerships with global OEMs, and the development of academic research centers. Across all regions, the convergence of policy support, capital infusion, and expanding talent pools is shaping a resilient outlook for the High‑Throughput Mass Spectrometer market.